Fachun Zhou

Prof. Fachun Zhou


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Molecular Immunology
Verified
Journal Article
Closed access
ZHZuotian Huang
Zuotian Huang
JPJunliang Pu
Junliang Pu
YLYunhai Luo
Yunhai Luo
JFJing Fan
Jing Fan
KLKaili Li
Kaili Li
FZFachun Zhou
Fachun Zhou

10 January 2025 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
QLQuanyi Lu
Quanyi Lu
XTXiyue Tang
Xiyue Tang
BTBailong Tao
Bailong Tao
KHKe Huang
Ke Huang
KLKaili Li
Kaili Li
FZFachun Zhou
Fachun Zhou

25 August 2023 in Cellular Signalling
Verified
Journal Article
Closed access
KLKaili Li
Kaili Li
ZHZuotian Huang
Zuotian Huang
CLChang Liu
Chang Liu
YXYuanyuan Xu
Yuanyuan Xu
WCWei Chen
Wei Chen
FZFachun Zhou
Fachun Zhou

1 July 2023 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
KLKaili Li
Kaili Li
XHXiaoxue Hu
Xiaoxue Hu
QLQuanyi Lu
Quanyi Lu
HZHeng Zhang
Heng Zhang
JZJiayi Zhou
Jiayi Zhou
FZFachun Zhou
Fachun Zhou
Background: To evaluate the risk factors and prognosis of patients with acute cholangitis recurrence. Methods: A total of 503 patients with acute cholangitis admitted to the First Affiliated Hospital of Chongqing Medical University between July 2013 and January 2022 were included in this retrospective observational study, who were followed up for 360 days and divided into relapse group and non-recurrence group according to the recurrence of acute cholangitis. Risk factors and prognosis of patients with acute cholangitis recurrence were analyzed by univariate, multivariate analyses and proportional hazards model. Results: A total of 161 patients with recurrent acute cholangitis were identified. Recurrent acute cholangitis usually occurred within 125 days; Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, Enterococcus faecalis, and Enterococcus faecium was the most common positive record both in blood and bile culture. In the multivariate analysis, abdominal pain (OR = 2.448, 95% CI = 1.196– 5.010, P = 0.014), bile stones (OR = 2.429, 95% CI = 1.024– 5.762, P = 0.044), diabetes (OR = 1.790, 95% CI = 1.007– 3.182, P = 0.047), pathogen (OR = 3.305, 95% CI = 1.932– 5.654, P< 0.001), and chronic kidney disease (OR = 2.500, 95% CI = 1.197– 5.221, P = 0.015) may be ascertained as the risk factors of acute cholangitis recurrence. The recurrence of acute cholangitis was identified as an independent risk factor for patient death (HR = 4.524, 95% CI = 1.426– 14.357, P = 0.010) by Cox proportional-hazards regression. Conclusion: Abdominal pain, bile stones, diabetes and chronic kidney disease may be risk factors of acute cholangitis recurrence. Patients with recurrent acute cholangitis have poor prognosis and high mortality. Early control of recurrent risk factors and active intervention are beneficial to high-risk patients.

19 May 2025 in Cellular & Molecular Biology Letters
Verified
Journal Article
Open access
PDF file
HFHongxue Fu
Hongxue Fu
BGBin Gao
Bin Gao
XZXin Zhou
Xin Zhou
YHYingting Hao
Yingting Hao
CLChang Liu
Chang Liu
FZFachun Zhou
Fachun Zhou
Sepsis-induced acute lung injury (ALI) is a clinical condition with high morbidity and mortality, and impaired endothelial function is the main pathological characteristic. As a member of DNA demethylases, ten-eleven translocation protein 2 (TET2) is involved in a variety of biological processes. However, the role of TET2 in endothelial dysfunction of sepsis-induced ALI remains unclear. We used cecal ligation and puncture (CLP) to establish a sepsis-induced acute lung injury mouse model and screened out Tet2 from TET family proteins. The results suggested that Tet2 was obviously declined. We used lipopolysaccharide (LPS) to stimulate human pulmonary microvascular endothelial cells (HPMECs) as an in vitro model, and we found the expression of TET2 was also decreased. Then we used small interfering RNAs and adenovirus to knockdown or overexpress TET2 to investigate the effect of TET2 on the function of HPMECs. The changes in sepsis-induced ALI symptoms were also analyzed in Tet2-deficient mice generated by adeno-associated virus 6 (AAV6). Next, RNA sequencing and KEGG analysis were used to find the TET2-regulated downstream target genes and signaling pathways under LPS stimulation. Finally, the rescue experiments were performed to analyze the role of target genes and signaling pathways modulated by TET2 in LPS-treated HPMECs. TET2 and 5-hmC levels were significantly decreased in both in vitro and in vivo models of sepsis-induced ALI. TET2 knockdown exacerbated the dysfunction and apoptosis of HPMECs induced by LPS. Conversely, TET2 overexpression significantly alleviated these dysfunctions and reduced apoptosis. Meanwhile, the lung injury of Tet2-deficient mice was aggravated by increased inflammation and apoptosis. RNA sequencing and subsequent experiments showed that TET2 overexpression could increase the expression of Integrin α10 (ITGA10) by reducing the methylation level of ITGA10 promoter. This, in turn, activated the PI3K-AKT signaling pathway. Knocking down ITGA10 weakened the beneficial effects of TET2 overexpression in LPS-stimulated endothelial cells. In our study, we demonstrated that TET2 deficiency aggravates endothelial cell dysfunction and promotes acute lung injury by targeting ITGA10 via the PI3K-AKT pathway. These findings indicate that TET2 may be a promising therapeutic target for treating sepsis-induced ALI.

1 December 2022 in Infection and Drug Resistance
Verified
Journal Article
Open access
PDF file
KLKaili Li
Kaili Li
SJSanle Jiang
Sanle Jiang
HFHongxue Fu
Hongxue Fu
YHYingting Hao
Yingting Hao
STShijing Tian
Shijing Tian
FZFachun Zhou
Fachun Zhou
Background: To identify the risk factors and prognosis of carbapenem-resistant organisms (CRO) in patients with acute cholangitis. Methods: This retrospective observational study was conducted to explore the risk factors and prognosis of CRO infection in 503 acute cholangitis patients diagnosed between July 2013 and January 2022 at the First Affiliated Hospital of Chongqing Medical University, who were divided into a CRO group and non-CRO group based on the presence or absence of CRO. Univariate, multivariate analyses, and the proportional hazards model were used to compare the risk factors and prognosis of CRO suffering in patients with acute cholangitis. Results: We identified 35 patients colonized with CRO from 503 acute cholangitis patients. In the multivariate analysis, tumor (OR=7.09, 95% CI=1.11– 45.30, P=0.038) and chronic kidney disease (OR=8.70, 95% CI=2.11– 35.88, P=0.003) were ascertained as the risk factors of the occurrence on CRO infection under the background of acute cholangitis. CRO infection was identified as an independent risk factor for acute cholangitis patient death (HR=5.147, 95% CI=1.475– 17.595, P=0.01) by Cox proportional-hazards regression. Conclusion: Tumor and chronic kidney disease may be risk factors for CRO infection. Patients diagnosed with acute cholangitis further infected with CRO had a poor prognosis and a more severe mortality. Active screening for CRO is expected to facilitate early prevention, diagnosis, and treatment of high-risk patients.